Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023467 (acute myeloid leukemia)
 35,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Acute myelogenous leukemia 11 years after successful treatment of Hodgkin's disease: A contribution to the problem of second malignancies. The occurence of a therapy resistant acute myelogenous leukemia 11 years after successful treatment (operation, radiotherapy, polychemotherapy) of Hodgkin's disease is described. While this second malignancy was rarely seen in the era of minimal or no therapy of Hodgkin's disease, it is nowadays described more often. The possible causes of this second malignant tumor are discussed. Although modern therapy of Hodgkin's disease should not be abandoned from fear of second malignancies, any change in primary treatment must consider not only acute toxicity but also the occurence of late second malignant tumors. Long term follow-up of all patients treated with radiotherapy and/or polychemotherapy is necessary.
 ...
PMID:[Acute myelogenous leukemia 11 years after successful treatment of Hodgkin's disease. A contribution to the problem of secondary tumors]. 27 96

Loss of certain red blood cell antigens has been described in various disease states including acute granulocytic leukemia (AGL). This paper describes the loss of blood group A antigen in three patients, two with AGL and a third with a myeloproliferative disorder similar to AGL which developed following total body irradiation for malignant, well-differentiated lymphocytic lymphoma. In the latter case, the onset of the myeloproliferative disease correlated with the loss of A antigen. In addition to A antigen loss, all three patients' red cells showed the loss of Lewis antigen, a finding previously unreported. Finally, the two patients with AGL also exhibited the loss of I antigen from their red cells.
Cancer 1978 Nov
PMID:Multiple red cell antigen loss in acute granulocytic leukemia. 28 Dec 59

Spontaneous sister chromatid exchanges and banded karyotypes were studied in blood lymphocytes from 96 individuals: seven patients with chronic myelogenous leukemia, 15 normal controls, and five "cancer families" comprising 12 cancer patients, 40 tumor-free blood relatives and 22 spouses. The families had: malignant melanoma; Epstein-Barr virus-associated malignancies and a birth defect syndrome; non-Hodgkin lymphoma and diverse carcinomas; Hodgkin's lymphoma and adenocarcinomas; and acute myelogenous leukemia. In addition to the Philadelphia chromosome in chronic myelogenous leukemia patients, karyotypic abnormalities, especially breaks and fragments, were found in 29% of cancer family members, but were inconsistent and usually attributable to radiotherapy. Mean sister chromatid exchange values were normal in chronic myelogenous leukemia, but low (by t-test) in tumor patients and their blood relatives in cancer-prone families. In tumor patients, mean sister chromatid exchange levels fell as age increased. After adjusting for this age effect, no significant differences remained among groups. In patients at high risk of cancer (because they have chronic myelogenous leukemia or a strong family history of cancer), spontaneous sister chromatid exchange rates were not a marker of cancer risk.
Int J Cancer 1979 Jan 15
PMID:Sister chromatid exchanges and chromosomes in chronic myelogenous leukemia and cancer families. 28 71

Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days. Cerebrospinal fluid examination prior to the last dosage of cytosine arabinoside revealed a mononuclear pleocytosis and increased protein. The neurological manifestations developed within one week after the last dose of Ara-C and persisted for over 8 weeks. Administration of intrathecal Ara-C in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild, transient neurological symptoms (paresthesias) in only one of 30 patients so treated.
Cancer 1979 Jan
PMID:Paraplegia following intrathecal cytosine arabinoside. 28 37

Autoradiography was used to demonstrate that the x-chromosome of the 45,X,-X,t(8;21) stemline of a female patient with acute myeloid leukemia (AML) was the active X-chromosome. This suggested that in patients housing AML with the 8;21 translocation, the loss of the inactive X-chromosome in females and of the Y in males (which is known to occur in nearly half of the patients) entails selective advantage to the stemline.
J Natl Cancer Inst 1979 Feb
PMID:Absence of late-replicating X-chromosome in a female patient with acute myeloid leukemia and the 8;21 translocation. 28 63

Acute myeloid leukaemia developed in a patient with psoriasis treated with oral 8-methoxypsoralen and longwave ultraviolet light (PUVA) 2 years earlier. Attention is called to the possibility that the effect of PUVA on DNA synthesis may not be limited to the areas of the skin being treated but - through damage to circulating multipotential stem cells - may also lead to haematological malignancies.
 ...
PMID:Development of acute myeloid leukaemia in a patient with psoriasis treated with oral 8-methoxypsoralen and longwave ultraviolet light. 28 81

The cases of three patients with acute myelocytic leukemia presenting during the second trimester of pregnancy are summarized. All three patients were treated with combination chemotherapy. One patient, while in remission, underwent elective abortion of an apparently normal fetus. This patient is alive and free of disease 2 years after bone marrow transplantation. Each of the other two patients was spontaneously delivered of a premature infant. Transient bone marrow suppression occurred in one of these infants. Both children were small for their gestational age. One patient died 9 days after her infant was delivered and the other survived for 13 months.
Cancer Treat Rep 1979 Mar
PMID:Combination chemotherapy for acute myelocytic leukemia during pregnancy: three case reports. 28 44

1-beta-D-Arabinosyl cytosine and methotrexate were studied for their antitumor activity in acute myeloid leukemia of the BN rat (BNML), which is characterized by a slow growth rate due to the presence of a high proportion of nonproliferating cells. It was found that the two drugs showed the maximal cytotoxic action when given separately. The effect was highly dependent on the interval between the administration of each drug. The variation of the cell kinetic parameters produced by the recruitment into cycle of the resting population, as determined by labeling indices, correlates well with the antileukemic action of the drug combination.
Cancer Chemother Pharmacol 1978
PMID:The relevance of cell kinetics for optimal scheduling of 1-beta-D-arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML). 28 66

We have identified trisomy 13 in two additional patients with hematologic malignancies involving the hematopoietic stem cell: a 75-year-old female with acute myelocytic leukemia and a 64-year-old female with agnogenic myelofibrosis and myeloid metaplasia. Chromosome analysis of the direct bone-marrow preparation showed 100% of cells with trisomy 13 in the first and 10% of cells in the second. We also previously reported a patient with Ph1 negative chronic myelogenous leukemia in whom 100% of the marrow cells showed an identical trisomy. The probability of finding three such patients in our case material was calculated to be 0.05--0.08, implying that trisomy 13 may be another nonrandom chromosomal aberration associated with malignancies of hematopoietic pluri-potent stem cell.
 ...
PMID:Trisomy 13 in bone marrow cells in acute myelocytic leukemia and myelofibrosis. 28 68

We have radiolabelled surface glycoproteins of different types of leukemic cell. The labelled proteins were separated by polyacrylamide slab gel electrophoresis and visualized by fluorography. Surface glycoprotein patterns discriminatory for acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) were found. We conclude that the analysis of the surface glycoprotein profile provides a useful method for the classification of leukemic cells according to cell type and stage of differentiation.
Int J Cancer 1979 Mar 15
PMID:Cell surface glycoprotein analysis: a diagnostic tool in human leukemias. 28 25


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>